eGenesis is a biotechnology company based in Cambridge, MA, dedicated to revolutionizing solid organ and therapeutic cell transplantation through its innovative multiplex gene editing and genome engineering platform. With a mission to address the critical shortage of transplantable organs, eGenesis is focused on developing Human Compatible (HuCo) organs and cells using advanced gene editing technologies. By pushing the boundaries of xenotransplantation, eGenesis aims to improve the lives of patients in need of transplants and their families.
Through its transformative research, eGenesis is committed to bridging the gap between the growing demand for organ transplants and the limited supply of human donor organs. By leveraging their EGEN Platform, eGenesis is working towards a future where the availability of transplantable organs and cells no longer determines the length or quality of one's life. With a particular focus on kidney and islet cells, eGenesis is at the forefront of innovation in xenotransplantation, offering hope and potential solutions to the transplant shortage crisis.
Generated from the website